New Gliwice, Poland manufacturing facility expands global footprint in Life Sciences market
ILC Dover to break ground on a new manufacturing site in Gliwice, Poland. (Credit: marcinjozwiak from Pixabay)
ILC Dover LP, specializing in innovative single-use and chemical workflow solutions for biotherapeutics and pharmaceutical processing, announced plans to break ground on a new 90,000 sq ft manufacturing site located in Gliwice, Poland in response to continued strong growth within its life sciences business. The state-of-the-art facility equipped with 20,000 sq ft of ISO Class 7 cleanroom capability will manufacture initially single-use powder bags, single-use liquid bags, and single-use fluid transfer assemblies. The new site will provide redundant supply capabilities, reduce the lead times for its European and Asian customers and manufacturing will be consistent with the Company’s global quality system.
The new site follows the Company’s recent announcement to significantly expand production capabilities in its existing Mexico facility in response to unprecedented growth and entry into new biotherapeutic markets. This expansion, in addition to the new facility in Poland, are the latest investments ILC Dover has made to advance the Company’s trajectory in growing its life sciences solutions for its global customer base including the biotherapeutic, cell & gene therapy, and pharmaceutical markets. The new facility in Gliwice, Poland is scheduled to come online in early 2023.
The facility will be home to 250 employees at full capacity – joining ILC Dover’s 2,000+ employees worldwide. It complements the Company’s current global biopharmaceutical manufacturing footprint in Juarez, Mexico, Frederica DE, Durham NC, Stockport UK, Rossens Switzerland, and Blarney Ireland.
“We are very excited to expand our global footprint in Poland with a new manufacturing facility equipped with the capacity to better serve our growing European and APAC customer base,” said Corey Walker, CEO of ILC Dover. “Providing critical solutions to the world’s leading life sciences customers remains top priority as our strategic investments center around ways to improve and optimize their workflows.”
Source: Company Press Release